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Abstract: In diabetic retinopathy, collapse of the retinal vasculature is associated with loss of 
the pericytes. These are contractile cells that together with endothelial cells form the terminal 
arterioles of the retina. The cause of the loss of pericytes is not known. Recently, it has been 
discovered that type 1 diabetes is caused by forbidden clones of cytotoxic T lymphocytes, which 
destroy the insulin-making cells with exquisite speciﬁ  city. In the light of this, I postulate that 
an antigenically-related forbidden clone of cytotoxic T lymphocytes selectively destroys the 
pericytes and that this is the cause of the vascular collapse of diabetic retinopathy. If this is so, 
the therapeutic implications are immense, involving a switch from ineffectual tight glycemic 
control to immunotherapy. This is already used as immunosuppression to prevent organ trans-
plant rejection, and as the immune ablation and autologous bone marrow cell reconstitution 
that has saved the lives of patients with lethally-severe scleroderma. Once the pericyte surface 
auto-antigen for the T lymphocytes has been isolated, selective destruction of the pathogenic 
T lymphocytes would be possible by manufacture and use of cytotoxic auto-antigen complexes, 
which arrests progression of the retinopathy.
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Etiology of Graves’ disease
The thyroid gland attracted clinical attention because its hormone, thyroxine, as shown 
by Harington (1933), contains iodine, a trace element. Surprisingly, our dietary supply 
of iodine, ultimately from soil, does not come from the weathering of rock, but through 
slow deposition by rainfall of iodine sublimed from the sea (Kelly and Sneddon 1960). 
Consequently, iodine deﬁ  ciency occurs in regions with newly formed soils, such as 
where mountains have been uplifted, as in Switzerland, India, Chile, and New Zealand. 
The deﬁ  ciency of iodine in these regions causes goitre, a hypertrophy of the thyroid 
gland, mediated by thyroid-stimulating hormone from the pituitary gland and prevent-
able by adding iodine to domestic salt. In New Zealand, 1 part of potassium iodide to 
20,000 parts of sodium chloride abolished the goitre endemic (Purves 1974).
A second thyroid disease, unrelated to iodine deﬁ  ciency, was discovered by 
Graves (1838). There is tachycardia, tremor, weight loss, thyroid enlargement, and 
exophthalmos. A century later, Adams and Purves (1980) discovered the causative 
agent, long-acting thyroid stimulator (LATS), which proved to be an autoantibody. 
Surprisingly, LATS, which was measured by a bioassay in guinea pigs or mice, 
was present in only about a third of thyrotoxic patients. However, a reﬁ  nement 
involving a neutralization step with human thyroid tissue revealed so-called LATS 
protector, another autoantibody, which correlated with degree of hyperthyroidism, 
and on infusion was active in stimulating the thyroid glands of several Otago Uni-
versity professors (Adams 1980). This showed that Graves’ disease is an autoim-
mune disease, caused by development of antibodies that accidentally react with a Clinical Ophthalmology 2008:2(2) 296
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host component instead of an invading microbial parasite 
(Adams and Knight 2003).
Fine variation in thyroid-stimulating 
autoantibodies
The thyroid gland’s thyrotropin receptor differs slightly in 
different animals, man, guinea pig, mouse, sheep, or cattle. 
LATS protector reacts with the human receptor but, unlike 
LATS, does not cross-react with the thyrotropin receptors of 
mice or guinea pigs (Adams 1980). The ﬁ  ne variation in the 
speciﬁ  city of the thyroid-stimulating autoantibodies, from 
patient to patient, is explained by Burnet’s forbidden clone 
theory (Burnet 1959), which postulates that autoimmunity 
arises by unlucky, semi-random, somatic mutations in the 
V (immunoglobulin variable region) genes of multiplying 
lymphocytes.
Eye complications of Graves’ disease
The exophthalmos of Graves’ disease has two components. 
One is a sympathetic nervous system reﬂ  ex retraction of 
the eyelids caused by high levels of thyroxine in the blood. 
The other is an increase in the bulk of the retro-globe tis-
sues, causing protrusion of the globe. Before antithyroid 
drugs were discovered by Kennedy (1942) in New Zealand 
and Astwood (1943) in Boston, there was mortality from 
Graves’ disease. This enabled Rundle and Pochin (1964) 
in London, to make ingenious post-mortem studies that 
showed the increase in bulk of the orbital tissues to be due 
to fat, there appearing to be a proliferation of adipose cells 
throughout the orbit.
Cross-tissue antibody auto-reactivity 
as the cause of exophthalmos
Interestingly, LATS, the human autoantibody that 
cross – reacts with the mouse thyrotropin receptor, correlates 
better with exophthalmos than with hyperthyroidism (Kriss 
et al 1967). In malignant exophthalmos, there is hypertrophy 
of the extra-ocular muscles. It seems that these muscles, in 
constant fast motion, use high caloriﬁ  c fatty acids for fuel 
instead of the usual glucose, like the wing muscles of birds, 
which accounts for the white meat of turkey breasts compared 
with the dark meat of their legs (Adams 1980). Some variants 
of the thyroid-stimulating autoantibodies apparently react 
with receptors on fat cells in the orbit, increasing the amount 
of fat there and sometimes depriving the extra-ocular muscle 
cells of fatty acids for their fuel, causing them to hypertrophy 
(Adams 1980). Pretibial myxoedema on the shins is another 
extra-thyroidal, cross-tissue manifestation of LATS variants 
and can be cured by topical application of corticosteroids 
(Kriss et al 1967).
Etiology of diabetes
It is now known that there are two distinct forms of diabetes 
(Sherwin 2000), type1 and type 2. Type 1 is an autoimmune 
disease caused by autoimmune destruction of the pancreatic 
islet beta cells that make insulin. The defect causing type 
2 diabetes is unknown. There is resistance to the action of 
insulin and a very strong genetic causation with near 100% 
concordance of identical twins. This compares with the 50% 
concordance in type 1 diabetes and other autoimmune dis-
eases where unlucky somatic mutations, with their random 
element, are necessary in lymphocyte genes for creation of 
the pathogenic forbidden clones.
A difference between Graves’ disease and type 1 diabetes 
is in the type of lymphocyte mutating into the forbidden clone. 
Mutations in B lymphocytes give rise to the plasma cells secret-
ing the thyroid-stimulating autoantibodies, whereas there is 
now clear evidence (Sherwin 2000; Adams and Knight 2003) 
that forbidden clones of cytotoxic T lymphocytes destroy the 
pancreatic islet insulin-making cells, with exquisite speciﬁ  city, 
leaving the other islet cells untouched. Cheynier and colleagues 
(1998) at the Pasteur Institute were the ﬁ  rst to demonstrate 
somatic mutation in the V genes of multiplying T cells, where 
it is rarer than in B cells because of the protective suppressor 
T cell phenomenon (Adams 1983).
Eye complications of diabetes
The major complication is diabetic retinopathy, in which the 
vasculature collapses, causing blindness, as described and 
illustrated by Klintworth (1988).
Loss of pericytes in diabetic 
retinopathy
The name pericyte derives from the Greek “kytos”, a hollow 
vessel, aptly describing a cell surrounding a terminal arteri-
ole. Unlike their associated endothelial cells, pericytes have 
contractile power and can be imagined as the last stage of the 
progression from arteries with multiple smooth muscle cells 
in their media to capillaries with no contractile ability.
In diabetic retinopathy, there is a loss of pericytes associ-
ated with vascular collapse (Klintworth 1988) as illustrated 
in Figure 1.
Autoantibodies to pericytes
These occur in people (Nayac et al 2005) and have a loose 
association with retinopathy, renal failure and hypertension. Clinical Ophthalmology 2008:2(2) 297
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Measured by a ﬂ  uorescence technique, using cultured bovine 
retinal cells, they do not show a causative relationship to 
retinopathy (Nayac et al 2007). They may reﬂ  ect damage to 
contractile blood vessels, including the retinal pericytes.
Cross-tissue T cell auto-reactivity 
as the cause of diabetic retinopathy
The cause of the loss of pericytes in diabetic retinopathy is 
not yet known. By analogy with the established cross-tissue 
B lymphocyte auto-reactivity of Graves’ disease, I postulate 
that cross-tissue T cell auto-reactivity is responsible. This 
would be analogous to the situation with the islet cell auto-
immunity, where the islet cell autoantibodies, discovered 
by Doniach and her colleagues (Bottazzo et al 1974) are not 
the destructive agents, but are passive consequences of the 
destruction by cytotoxic T cell forbidden clones.
Therapeutic implications
The therapeutic implications are immense, involving a 
switch from tight glycemic control, which does not prevent 
retinopathy, to immunotherapy by immunosuppression or 
by elimination of the T lymphocyte pathogenic forbidden 
clones. Immunosuppression is already widely familiar, 
being in use for prevention of rejection of organ transplants. 
Recently, Englert and her colleagues (2005) saved the 
lives of three patients with systemic scleroderma of lethal 
severity. By destroying the patients’ immune systems with 
immuno-suppressive chemotherapy, they got rid of their 
lethally-dangerous ﬁ  broblast-stimulating forbidden clones 
(Adams and Knight 2003), then restored their immune sys-
tems with stem cells previously taken from each patient’s 
own bone marrow. This autologous bone marrow grafting 
(Applebaum 2005) was necessary to prevent their patients 
from dying of microbial infections in the absence of their 
destroyed immunity systems. Because forbidden clones of 
B or T lymphocytes arise by unlucky somatic mutations in 
their V genes, during the multiplication of lymphocytes in the 
periphery (Adams and Knight 2003), they are very unlikely to 
reappear in the new, regenerated immune system. An alterna-
tive method for destroying the immune system would have 
been the use of total lymphoid irradiation (Fisher et al 2005). 
This too would have destroyed the forbidden clones of lym-
phocytes that were causing their patients’ life-endangering 
systemic scleroderma.
For therapy of diabetic retinopathy and nephropathy, 
immunosuppression needs urgent trial and following this, 
for severe cases immune ablation and autologous bone mar-
row cell reconstitution would be appropriate (Adams 2006). 
Research to isolate the pericyte auto-antigen reactive with 
T cells is an urgent necessity and will enable ideal therapy 
in the form of selective destruction of the pathogenic forbid-
den clones, by manufacture and use of cytotoxic-autoantigen 
complexes, with the rest of the immunity system left 
untouched (Adams and Knight 2003).
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